Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). June 2026 corporate presentation filed as Exhibit 99.1, potentially updating investors on Dianthus’s strategy and pipeline.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- June 2026 corporate presentation filed as Exhibit 99.1, potentially updating investors on Dianthus’s strategy and pipeline
- Filing signed June 12, 2026 by Adam M. Veness, SVP, General Counsel and Secretary
Item EX-99.1 · Exhibit EX-99.1
- Claseprubart Phase 2 gMG results support potential best-in-disease positioning, with statistically significant improvements across five key efficacy measures at 300mg/2mL Q2W
- 65 participants enrolled; 300mg/2mL achieved MG-ADL change of -4.6 vs -2.8 for placebo at Week 13
- 300mg/2mL arm delivered QMG change of -4.4 vs -2.0 for placebo and 37% Minimal Symptom Expression
- Favorable Phase 2 safety profile, including no serious related infections, no discontinuations from related adverse events, and no boxed warning/REMS signal
- 2026 catalysts include Phase 3 gMG initiation midyear, Phase 2 MMN top-line data in Q4, and CIDP Part B guidance by year-end
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.